Insider Trading Activity - FibroGen, Inc (NASDAQ:FGEN)

FibroGen, Inc (NASDAQ:FGEN) insider K Peony Yu sold 2,851 shares of the company's stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $49.45, for a total value of $140,981.95. Following the sale, the insider now directly owns 185,546 shares of the company's stock, valued at approximately $9,462,846. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. William Blair reissued an outperform rating on shares of FibroGen in a research note on Wednesday, August 9th. The shares were sold at an average price of $50.61, for a total value of $4,807,950.00. The shares were sold at an average price of $33.97, for a total transaction of $962,913.62. The stock of TJX Companies Inc (NYSE:TJX) earned "Buy" rating by BMO Capital Markets on Thursday, June 8. The shares were sold at an average price of $34.00, for a total transaction of $136,000.00.

On Monday, June 19th, Pat Cotroneo sold 5,500 shares of FibroGen stock. The shares were sold at an average price of $32.00, for a total transaction of $96,000.00. Equity analyst Jefferies began coverage setting a rating of "Buy". The company's market cap is $1.52 billion. Company shares last traded at $52.40 quite a bit above the 50 day moving average which is $43.31 and which is impressively higher than the 200 day moving average of $32.07. Nasdaq.com's news article titled: "FibroGen, Inc". The firm has "Buy" rating by Jefferies given on Monday, August 14. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.01). On Friday, December 4 the stock rating was initiated by Citigroup with "Buy". They expect $1.00 EPS, up 9.89% or $0.09 from last year's $0.91 per share.

WARNING: This piece was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & global copyright and trademark law. The original version of this news story can be read at https://www.truebluetribune.com/2017/09/16/fibrogen-inc-fgen-vp-sells-140981-95-in-stock.html. Teacher Retirement System of Texas increased its position in FibroGen by 15.7% in the second quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company's stock valued at $218,000 after acquiring an additional 412 shares in the last quarter. Jefferies Group LLC now has a $75.00 target price on the biopharmaceutical company's stock. Omega Fund Management, LLC claims 627,492 shares valued at $20,268,000. FMR LLC lifted its holdings in FibroGen by 96.9% in the 2nd quarter.

Rory B. Riggs, Director let go of $1,298,000 worth of shares at an average price of $51.92 on September 13th. State Street Corp lifted its holdings in FibroGen by 16.4% in the 2nd quarter. Finally, Fox Run Management L.L.C. increased its position in FibroGen by 15.0% in the third quarter. Janus Capital Management LLC added to its position by buying 14,882 shares an increase of 1.1% from 12/31/2016 to 03/31/2017. Gluskin Sheff And Assoc has invested 0.48% in TJX Companies Inc (NYSE:TJX).

A number of equities research analysts recently issued reports on FGEN shares. Kbc Group Nv holds 0.17% in TJX Companies Inc (NYSE:TJX) or 233,947 shares. Credit Suisse has "Outperform" rating and $40 target. Citigroup Inc. boosted their target price on shares of FibroGen from $48.00 to $65.00 and gave the stock a top pick rating in a research note on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. FibroGen has an average rating of "Buy" and an average price target of $60.17.

FibroGen, Inc., launched on September 29, 1993, is a science-based biopharmaceutical company. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Altre Notizie